Ask about this productRelated genes to: CYP2J2 antibody
- Gene:
- CYP2J2 NIH gene
- Name:
- cytochrome P450 family 2 subfamily J member 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 1p32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1996-06-21
- Date modifiied:
- 2016-10-05
Related products to: CYP2J2 antibody
Related articles to: CYP2J2 antibody
- Chronic Obstructive Pulmonary Disease (COPD) remains a major global health challenge due to the lack of therapies that modify its disease progression. Qingfei Tongluo Formula (QFTLF), a classic TCM formula, has shown efficacy in COPD. However, its specific molecular mechanisms and active compounds remain undefined. - Source: PubMed
Publication date: 2026/05/16
Wang YanruTian YawenBai JiaxuZhao JialiSun HailongHu GuangYao JuanLiu XuefengZhang ZhimingJin XiaojieLiu Yongqi - Parkinson's disease (PD) is a severe neurodegenerative disorder marked by progressive dopaminergic loss, oxidative stress, metabolic dysregulation, and neuroinflammation. Umbilical cord blood-derived exosomes (UCB-Exos) have emerged as a promising cell-free therapeutic strategy, yet the precise molecular mechanisms underlying their neuroprotective properties remain largely unknown. This study highlights Peroxiredoxin-2 (PRDX2) as an important antioxidant protein within UCB-Exos that mediates their neuroprotective effects in PD models. Using advanced multi-omics approaches, including proteomics, metabolomics, and transcriptomics, we demonstrate that PRDX2 is selectively enriched in UCB-Exos compared to peripheral blood-derived exosomes. UCB-Exos, through the delivery of PRDX2, partially restore antioxidant defenses in neurons, attenuate neuroinflammation, and promote cellular survival. Moreover, UCB-Exos were found to modulate arachidonic acid metabolism by upregulating the levels of 8,9-epoxyeicosatrienoic acid (8,9-EET), a key metabolite with anti-inflammatory properties. Mechanistically, PRDX2 appears to protect the enzyme CYP2J2 from oxidative degradation, facilitating the production of 8,9-EET and reducing the NF-κB/COX-2-driven inflammatory response, thus potentially mitigating neurodegeneration. This study provides evidence for a potential pathway, the PRDX2-mediated metabolic regulatory pathway, and highlights the therapeutic potential of UCB-Exos, offering a novel strategy in the development of exosome-based treatments targeting oxidative stress and neuroinflammation in neurodegenerative diseases. - Source: PubMed
Publication date: 2026/05/25
Weng JingjingZuo DianbaoYan WeiDong JinjuZhu MengtingYe JunjieWang PuqingSun XiaodongSang Ming - Menopause is associated with a marked increase in cardiac hypertrophy and progression to heart failure with preserved ejection fraction (HFpEF), a condition that disproportionately affects women and lacks effective targeted therapies. Although estrogen deficiency has long been implicated in postmenopausal cardiac remodeling, emerging evidence highlights a critical role for cytochrome P450 (CYP)-derived arachidonic acid metabolites as central regulators of myocardial structure and function. In a healthy premenopausal heart, a balance between cardioprotective epoxyeicosatrienoic acids (EETs), produced by the CYP2J2 and CYP2C enzymes, and the pro-hypertrophic metabolite 20-hydroxyeicosatetraenoic acid (20-HETE), produced by the CYP4A and CYP4F isoforms, supports adaptive remodeling and diastolic function. Menopause disrupts this equilibrium by estrogen-mediated reprogramming of CYP expression and activity, leading to diminished EET bioavailability, heightened 20-HETE signaling, and accelerated EETs breakdown by soluble epoxide hydrolase (sEH). This metabolic shift induces oxidative stress, calcium imbalance, fibroblast activation, extracellular matrix buildup, and cardiomyocyte enlargement, which together lead to ventricular stiffness and diastolic failure. This review aims to consolidate contemporary experimental and translational evidence linking CYP-derived eicosanoids to menopause-related cardiac hypertrophy and to assess novel non-hormonal therapeutic approaches, including sEH inhibitors, stable EET analogs, and CYP4A/20-HETE inhibitors, that target these molecular pathways. Targeting CYP-derived metabolites represents a promising mechanism-based approach to prevent or reverse postmenopausal cardiac hypertrophy and to modify the natural history of HFpEF. Importantly, these non-hormonal strategies may offer a safer therapeutic alternative to hormone replacement therapy by avoiding the systemic risks associated with exogenous estrogen exposure while directly targeting disease-specific molecular pathways. - Source: PubMed
Publication date: 2026/05/12
Abd El-Aziz Mostafa KShalaby Ali HEl-Mahrouk Sara REl-Kadi Ayman O S - Direct oral anticoagulants (DOACs) exhibit considerable individual variability in effectiveness and bleeding risk, possibly due to genetic differences. This study assessed how genetic polymorphisms impact the pharmacokinetics (PK) and outcomes of DOACs. - Source: PubMed
Publication date: 2026/04/14
Chai HuaruHuo JianiChen Hao - Tongue squamous cell carcinoma (TSCC) is clinically heterogeneous, and patients with a similar TNM stage can experience markedly different outcomes. We systematically reviewed omics-driven studies to identify prognostic TSCC biomarkers. Although fundamentally prognostic, we discussed their theoretical translational relevance regarding future clinical decisions-such as treatment stratification or surveillance intensity-while strictly framing them as preliminary, hypothesis-generating targets. PubMed, Scopus, Web of Science, and Cochrane were searched for original human studies published between 2014 and 2024 using high-throughput genomic or transcriptomic profiling. Study selection followed referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), data were extracted with a structured workbook, and risk of bias was assessed using QUIPS and PROBAST, with reporting completeness appraised using REMARK. Seventeen studies were included, identifying 85 distinct biomarkers. Across biomarkers supported by multivariable overall survival analyses, higher-risk associations were reported for , , , , and , whereas lower-risk associations were reported for , , , , and . Recurrent biological themes included IL-17 signaling, ECM-receptor interaction, and focal adhesion. was the only biomarker reported in more than one included study, supporting its prioritization for validation. Although the evidence remains heterogeneous and largely hypothesis-generating, these markers may support the future validation of response-oriented therapeutic stratification in TSCC. - Source: PubMed
Publication date: 2026/04/10
Astreidis IoannisKostidis IliasMalousi AndigoniParaskevopoulos KonstantinosAndreadis DimitriosVahtsevanos KonstantinosVizirianakis Ioannis